July 11, 2017
VIA EDGAR
Ms. Suzanne Hayes
Mr. Chris Edwards
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | KaloBios Pharmaceuticals, Inc. |
Registration Statement on Form S-1 (File No. 333-216799)
Request for Acceleration of Effective Date
Dear Mr. Edwards:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, KaloBios Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of the above-referenced Registration Statement, so that it may become effective at 9:00 a.m. Eastern Time on July 14, 2017, or as soon thereafter as practicable.
Sincerely, | |
/s/ David Tousley | |
| Interim Chief Financial Officer | |
| KaloBios Pharmaceuticals, Inc. |
cc:
Cameron Durrant,
Chief Executive Officer
KaloBios Pharmaceuticals, Inc.
Kevin L. Vold
Polsinelli PC